Literature DB >> 26863111

Serum angiogenic profile in abnormal placentation.

Ebru Biberoglu1, Ayse Kirbas1, Korkut Daglar1, Kutay Biberoglu2, Hakan Timur1, Canan Demirtas3, Erdem Karabulut4, Nuri Danisman1.   

Abstract

OBJECTIVE: To evaluate the circulating soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) levels in women with abnormal placentation and to compare the data with the results of women with normal pregnancy.
MATERIAL AND METHODS: Serum biomarkers of angiogenesis and maternal and perinatal characteristics of 68 pregnant women, all in the third trimester, who were diagnosed to have vaginal bleeding due to complete placenta previa with and without concomitant placenta accreta, increta and percreta as the study group and 30 pregnant women without any placentation abnormality who eventually delivered at  ≥37 weeks of gestational age as the control group were evaluated.
RESULTS: There was no statistical difference in the maternal serum values of sFlt1, PlGF, sFlt1/PlGF ratio and VEGF in groups with placental abnormality as compared to controls. Not even a single case of preeclampsia and intrauterine fetal growth restriction was encountered in the study group.
CONCLUSION: We demonstrated that regardless of the localization and the degree of the myometrial invasion of the placenta in the uterus, the circulatory biomarkers of angiogenesis and vascularization were comparable.

Entities:  

Keywords:  Angiogenesis; abnormally invasive placenta; placenta previa; placental growth factor; soluble Fms-like tyrosine kinase 1; vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 26863111     DOI: 10.3109/14767058.2015.1118044

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  5 in total

1.  Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.

Authors:  Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Steven J Korzeniewski; Eli Maymon; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Zhong Dong; Offer Erez; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

Review 2.  Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum.

Authors:  Tianyue Zhang; Shaowei Wang
Journal:  Front Med (Lausanne)       Date:  2022-05-30

3.  Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.

Authors:  Hacer Uyanıkoğlu; Adnan İncebıyık; Ahmet B Turp; Güler Çakmak; Sibel Sak; Neşe G Hilali
Journal:  Balkan Med J       Date:  2017-09-13       Impact factor: 2.021

4.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

5.  Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study.

Authors:  Alexander Schwickert; Frédéric Chantraine; Loreen Ehrlich; Wolfgang Henrich; Mustafa Zelal Muallem; Andreas Nonnenmacher; Philippe Petit; Katharina Weizsäcker; Thorsten Braun
Journal:  Reprod Sci       Date:  2020-10-06       Impact factor: 3.060

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.